Health Care [ 9/12 ] | Biotechnology [ 43/74 ]
NASDAQ | Common Stock
Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States.
The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.
It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor.
The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018.
Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 13, 25 | -0.44 Increased by +71.43% | -0.40 Decreased by -10.00% |
| Aug 14, 25 | -0.45 Increased by +87.57% | -0.36 Decreased by -25.00% |
| May 7, 25 | -0.94 Decreased by -10.34% | - |
| Mar 31, 25 | -0.85 Increased by 0.00% | -1.23 Increased by +30.89% |
| Nov 14, 24 | -1.54 Decreased by -35.09% | -4.14 Increased by +62.80% |
| Aug 14, 24 | -3.62 Decreased by -145.47% | -4.59 Increased by +21.13% |
| Apr 1, 24 | -0.85 Increased by +73.05% | -1.30 Increased by +34.62% |
| Mar 20, 24 | -0.85 Increased by +64.58% | -1.30 Increased by +34.62% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 0.00 Decreased by N/A% | -2.39 M Decreased by -56.96% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -2.17 M Decreased by -17.33% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by -100.00% | -1.77 M Increased by +17.87% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 70.00 K Increased by +N/A% | -1.63 M Increased by +14.20% | Decreased by -2.32 K% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -1.52 M Increased by +45.18% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -1.85 M Increased by +27.58% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 30.00 K Increased by +N/A% | -2.15 M Increased by +40.20% | Decreased by -7.18 K% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -1.90 M Increased by +30.61% | Decreased by N/A% Decreased by N/A% |